<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332017000300297</article-id>
<article-id pub-id-type="doi">10.1016/j.rccar.2016.06.004</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Cardiomiopatía hipertrófica: experiencia de 5 años]]></article-title>
<article-title xml:lang="en"><![CDATA[Hypertrophic cardiomyopathy: 5 year experience]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Dávila]]></surname>
<given-names><![CDATA[Fabián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[Antonio J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mogollón]]></surname>
<given-names><![CDATA[Iván R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendoza]]></surname>
<given-names><![CDATA[Fernán]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guatibonza]]></surname>
<given-names><![CDATA[Diego A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Fundación Clínica Shaio  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Clínica Shaio  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Fundación Clínica Shaio  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>24</volume>
<numero>3</numero>
<fpage>297</fpage>
<lpage>297</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332017000300297&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332017000300297&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332017000300297&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  La cardiomiopatía hipertrófica se define como el engrosamiento de la pared ventricular izquierda que no es explicado por condiciones anormales de la carga y que impone un riesgo de: arritmias, falla cardiaca y muerte súbita.  Objetivo:  identificar prevalencia, las características clínicas y el tratamiento de los pacientes con cardiomiopatía hipertrófica atendidos en nuestra institución.  Materiales y métodos:  Se extrajeron y analizaron los registros de pacientes con cardiomiopatías hipertróficas, definiendo las características generales y explorando las diferencias entre subgrupos, todos los contrastes estadísticos asumieron una confianza del 95%.  Resultados:  Se evaluaron 22 casos de la cardiomiopatía hipertrófica, el sexo femenino aportó el 40,9% del total de los casos, la edad promedio fue 54 años. El 77,27% presentaron insuficiencia mitral, el 63,64% reportaron dolor torácico, el 68,18% se encontraban en tratamiento inhibidor de renina y el 95,45% tenían betabloqueador, el grosor promedio del septum fue del 22,77 mm, la prevalencia de fibrilación auricular fue del 22,7% y la de enfermedad coronaria del 18%.  Conclusiones:  La prevalencia de la cardiomiopatía hipertrófica en el período 2009-2013 fue del 2,35%, relacionado principalmente con la insuficiencia mitral y tenían antecedente de dolor torácico, la prevalencia de la fibrilación auricular en pacientes con cardiomiopatía hipertrófica en el presente estudio fue del 22,7% y la de enfermedad coronaria del 18%.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  Hypertrophic cardiomyopathy is defined as the thickening of the left ventricular wall that is not explained by abnormal loading conditions, imposing a risk for arrhythmias, heart failure and sudden death. We attempt to identify the prevalence, clinical features and treatment of patients with hypertrophic cardiomyopathy assisted within our institution.  Material and methods:  Records of patients with hypertrophic cardiomyopathy were pulled and analysed, defining general features and exploring differences among subgroups; all statistical contrasts assumed a confidence of 95%.  Results:  22 cases of hypertrophic cardiomyopathy were assessed, 40.9% of whom were female, average age was 54. 77.27% showed mitral insufficiency, 63.4% reported chest pain, 68.18% were receiving renin inhibitor therapy and 95.45% were taking beta blockers. Average septum thickness was 22.77 mm, prevalence of atrial fibrillation was 22.7% and coronary disease 18%.  Conclusion:  Prevalence of hypertrophic cardiomyopathy during the 2009-2013 period was of 2.35%, mostly related to mitral insufficiency and previous history of chest pain; prevalence of atrial fibrillation in patients with hypertrophic cardiomyopathy in our study was of 22.7%,and 28% for coronary disease.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Dolor torácico]]></kwd>
<kwd lng="es"><![CDATA[Miocardiopatía hipertrófica]]></kwd>
<kwd lng="es"><![CDATA[Muerte súbita cardiaca]]></kwd>
<kwd lng="es"><![CDATA[Taquiarritmias]]></kwd>
<kwd lng="es"><![CDATA[Fibrilacion auricular]]></kwd>
<kwd lng="en"><![CDATA[Chest pain]]></kwd>
<kwd lng="en"><![CDATA[Hypertrophic cardiomyopathy]]></kwd>
<kwd lng="en"><![CDATA[Sudden cardiac death]]></kwd>
<kwd lng="en"><![CDATA[Tachyarrhythmias]]></kwd>
<kwd lng="en"><![CDATA[Atrial fibrillation]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>J Am Coll Cardiol</collab>
<article-title xml:lang=""><![CDATA[ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2011</year>
<volume>58</volume>
<page-range>212-60</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alcalai]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Seidman]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Seidman]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic basis of hypertrophic cardiomyopathy: From bench to the clinics.]]></article-title>
<source><![CDATA[J Cardiovasc Electrophysiol.]]></source>
<year>2008</year>
<volume>19</volume>
<page-range>104-10</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2010</year>
<volume>121</volume>
<page-range>445-56</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<collab>J Am Coll Cardiol</collab>
<article-title xml:lang=""><![CDATA[American College of Cardiology/Europena Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2003</year>
<volume>42</volume>
<page-range>1687-713</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<collab>European Heart Journal</collab>
<article-title xml:lang=""><![CDATA[Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)]]></article-title>
<source><![CDATA[Eur Hear J]]></source>
<year>2014</year>
<volume>35</volume>
<page-range>2733-99</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertrophic cardiomyopathy: An important global disease.]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2004</year>
<volume>116</volume>
<page-range>63-5</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2006</year>
<volume>114</volume>
<page-range>216-25</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Poloniecki]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dickie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Monserrat]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Varnava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sudden death in hypertrophic cardiomyopathy identification of high risk patients]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2000</year>
<volume>36</volume>
<page-range>2212-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Akhondzadeh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Naghavi]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Vazirian]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shayeganpour]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rashidi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Khani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Passionflower in the treatment of generalized anxiety a pilot double-blind randomized controlled trial with oxazepam]]></article-title>
<source><![CDATA[J Clin Pharm Ther]]></source>
<year>2001</year>
<volume>26</volume>
<page-range>363-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agarwal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tuzcu]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Smedira]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lever]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Lytle]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[J Am Coll Cardiol.]]></source>
<year>2010</year>
<volume>55</volume>
<page-range>823-34</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nistri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[B blockers for prevention of exercise induced left ventricular outflow tract obstruction in patients with cardiomyopathy.]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Hauser]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Aeppli]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical course of hypertrophic cardiomyopathy with survival to advanced age]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2003</year>
<volume>42</volume>
<page-range>882</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorajja]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Valeti]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Rihal]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Gersh]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2008</year>
<volume>118</volume>
<page-range>131-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olivotto]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ommen]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surgical Myectomy Versus Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. Will There Ever Be a Randomized Trial?]]></article-title>
<source><![CDATA[J Am Coll Cardiol.]]></source>
<year>2007</year>
<volume>50</volume>
<page-range>831-4</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morrow]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Reitz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Redwood]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Operative treatment in hypertrophic subaortic stenosis Techniques, and the results of pre and postoperative assessments in 83 patients]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1975</year>
<volume>52</volume>
<page-range>88-102</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
